HRP20130982T1 - Roflumilast za lijeäśenje pulmonalne hipertenzije - Google Patents
Roflumilast za lijeäśenje pulmonalne hipertenzije Download PDFInfo
- Publication number
- HRP20130982T1 HRP20130982T1 HRP20130982TT HRP20130982T HRP20130982T1 HR P20130982 T1 HRP20130982 T1 HR P20130982T1 HR P20130982T T HRP20130982T T HR P20130982TT HR P20130982 T HRP20130982 T HR P20130982T HR P20130982 T1 HRP20130982 T1 HR P20130982T1
- Authority
- HR
- Croatia
- Prior art keywords
- pulmonary
- hypertension
- arterial hypertension
- pulmonary arterial
- roflumilast
- Prior art date
Links
- 208000002815 pulmonary hypertension Diseases 0.000 title claims 12
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 title claims 6
- 229960002586 roflumilast Drugs 0.000 title claims 6
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 5
- PCGSQNPMMSALEJ-UHFFFAOYSA-N roflumilast n-oxide Chemical compound ClC1=C[N+]([O-])=CC(Cl)=C1NC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 PCGSQNPMMSALEJ-UHFFFAOYSA-N 0.000 claims 5
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 230000007954 hypoxia Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 208000027932 Collagen disease Diseases 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 3
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 3
- 208000015872 Gaucher disease Diseases 0.000 claims 3
- 208000031886 HIV Infections Diseases 0.000 claims 3
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 claims 3
- 208000021124 Heritable pulmonary arterial hypertension Diseases 0.000 claims 3
- 208000020875 Idiopathic pulmonary arterial hypertension Diseases 0.000 claims 3
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 3
- 208000024799 Thyroid disease Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000007345 glycogen storage disease Diseases 0.000 claims 3
- 208000034737 hemoglobinopathy Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- 208000018337 inherited hemoglobinopathy Diseases 0.000 claims 3
- 208000007232 portal hypertension Diseases 0.000 claims 3
- 238000010911 splenectomy Methods 0.000 claims 3
- 239000003053 toxin Substances 0.000 claims 3
- 231100000765 toxin Toxicity 0.000 claims 3
- 108700012359 toxins Proteins 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 2
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000000122 hyperventilation Diseases 0.000 claims 2
- 230000000870 hyperventilation Effects 0.000 claims 2
- 210000001147 pulmonary artery Anatomy 0.000 claims 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 2
- 230000009424 thromboembolic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (12)
1. Uporaba, naznačena time, da se spoj odabran iz skupine koja sadrži roflumilast, farmaceutski prihvatljivu sol od roflumilasta, roflumilast-N-oksid i farmaceutski prihvatljivu sol od roflumilast-N-oksida, upotrebljava za proizvodnju farmaceutskog sastava za preventivno liječenje pulmonalne hipertenzije.
2. Uporaba prema zahtjevu 1, naznačena time, da je spoj odabran iz skupine koja sadrži roflumilast i farmaceutski prihvatljivu sol od roflumilasta.
3. Uporaba prema zahtjevu 1, naznačena time, da je spoj odabran iz skupine koja sadrži roflumilast-N-oksid i farmaceutski prihvatljivu sol od roflumilast-N-oksida.
4. Uporaba prema zahtjevu 1, naznačena time, da spoj je roflumilast.
5. Uporaba prema zahtjevu 1, naznačena time, da spoj je roflumilast-N-oksid.
6. Uporaba prema bilo kojem od zahtjeva 1 do 5, naznačena time, da se pulmonalna hipertenzija odnosi na oblik pulmonalne hipertenzije, koji je odabran iz skupine koju čine idiopatska pulmonalna arterijska hipertenzija; obiteljska pulmonalna arterijska hipertenzija; pulmonalna arterijska hipertenzija povezana s vaskularnom kolagenozom, urođenim sistemsko-pulmonalnim račvanjima, portalnom hipertenzijom, HIV-infekcijom, drogama ili toksinima; pulmonalna arterijska hipertenzija povezana s tiroidnim poremećajima, poremećajem skladištenja glikogena, Gaucherovom bolešću, nasljednom hemoragijskom teleangiektazijom, hemoglobinopatijama, mijeloproliferativnim poremećajima ili splenektomijom; pulmonalna arterijska hipertenzija povezana s pulmonalno-kapilarnom hemangiomatozom; trajna pulmonalna arterijska hipertenzija kod novorođenčadi; pulmonalna arterijska hipertenzija povezana s kroničnom opstrukcijskom bolešću dišnih putova, intersticijalnom plućnom bolešću, hipoksijom izazvanim poremećajima alveolarne hiperventilacije, hipoksijom izazvanim poremećajima disanja kod spavanja ili kroničnim izlaganjem visokim nadmorskim visinama; pulmonalna arterijska hipertenzija povezana s nenormalnim razvojem; te pulmonalna arterijska hipertenzija uzrokovana tromboemboličkom opstrukcijom distalnih pulmonalnih arterija.
7. Uporaba prema bilo kojem od zahtjeva 1 do 5, naznačena time, da se pulmonalna hipertenzija odnosi na oblik pulmonalne hipertenzije, koji je odabran iz skupine koju čine idiopatska pulmonalna arterijska hipertenzija; obiteljska pulmonalna arterijska hipertenzija; pulmonalna arterijska hipertenzija povezana s vaskularnom kolagenozom, urođenim sistemsko-pulmonalnim račvanjima, portalnom hipertenzijom, HIV-infekcijom, drogama ili toksinima; pulmonalna arterijska hipertenzija povezana s tiroidnim poremećajima, poremećajem skladištenja glikogena, Gaucherovom bolešću, nasljednom hemoragijskom teleangiektazijom, hemoglobinopatijama, mijeloproliferativnim poremećajima ili splenektomijom; pulmonalna arterijska hipertenzija povezana s pulmonalno-kapilarnom hemangiomatozom; trajna pulmonalna arterijska hipertenzija kod novorođenčadi; pulmonalna arterijska hipertenzija povezana s intersticijalnom plućnom bolešću, hipoksijom izazvanim poremećajima alveolarne hiperventilacije, hipoksijom izazvanim poremećajima disanja kod spavanja ili kroničnim izlaganjem visokim nadmorskim visinama; pulmonalna arterijska hipertenzija povezana s nenormalnim razvojem; te pulmonalna arterijska hipertenzija uzrokovana tromboemboličkom opstrukcijom distalnih pulmonalnih arterija.
8. Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na idiopatsku pulmonalnu arterijsku hipertenziju.
9. Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na obiteljsku pulmonalnu arterijsku hipertenziju.
10. Uporaba prema zahtjevu 6, naznačena time, da se pulmonalna hipertenzija odnosi na pulmonalnu hipertenziju koja je povezana s kroničnom opstrukcijskom plućnom bolešću.
11. Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na pulmonalnu arterijsku hipertenziju koja je povezana s vaskularnom kolagenozom, urođenim sistemsko-pulmonalnim račvanjima, portalnom hipertenzijom, HIV-infekcijom, drogama ili toksinima.
12. Uporaba prema jednom od zahtjeva 6 ili 7, naznačena time, da se pulmonalna hipertenzija odnosi na pulmonalnu arterijsku hipertenziju koja je povezana s tiroidnim poremećajima, poremećajem skladištenja glikogena, Gaucherovom bolešću, nasljednom hemoragijskom teleangiektazijom, hemoglobinopatijama, mijeloproliferativnim poremećajima ili splenektomijom.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05103147 | 2005-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20130982T1 true HRP20130982T1 (hr) | 2013-11-22 |
Family
ID=34939388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20130982TT HRP20130982T1 (hr) | 2005-04-19 | 2013-10-16 | Roflumilast za lijeäśenje pulmonalne hipertenzije |
Country Status (24)
Country | Link |
---|---|
US (1) | US8648100B2 (hr) |
EP (2) | EP1874309A1 (hr) |
JP (2) | JP2008536888A (hr) |
KR (1) | KR101358479B1 (hr) |
CN (2) | CN102614176A (hr) |
AU (1) | AU2006237300B2 (hr) |
BR (1) | BRPI0610498A2 (hr) |
CA (1) | CA2604295C (hr) |
CY (1) | CY1114468T1 (hr) |
DK (1) | DK2366393T3 (hr) |
EA (1) | EA016037B1 (hr) |
ES (1) | ES2433661T3 (hr) |
HR (1) | HRP20130982T1 (hr) |
IL (2) | IL186538A0 (hr) |
ME (1) | ME01609B (hr) |
MX (1) | MX2007012711A (hr) |
NO (1) | NO20075662L (hr) |
NZ (1) | NZ561746A (hr) |
PL (1) | PL2366393T3 (hr) |
PT (1) | PT2366393E (hr) |
RS (1) | RS52944B (hr) |
SI (1) | SI2366393T1 (hr) |
WO (1) | WO2006111495A1 (hr) |
ZA (1) | ZA200707930B (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009013286A1 (en) * | 2007-07-24 | 2009-01-29 | Novartis Ag | Organic compounds |
WO2009115235A1 (en) * | 2008-03-20 | 2009-09-24 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of pulmonary hypertension |
DK2948148T3 (da) * | 2013-01-28 | 2020-10-26 | Incozen Therapeutics Pvt Ltd | Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid |
WO2015089105A1 (en) | 2013-12-09 | 2015-06-18 | Respira Therapeutics, Inc. | Pde5 inhibitor powder formulations and methods relating thereto |
CN107038965A (zh) * | 2017-05-05 | 2017-08-11 | 深圳浩翔光电技术有限公司 | Led显示装置、成型模组、及其生产工艺 |
KR20190005708A (ko) | 2017-07-05 | 2019-01-16 | 이화여자대학교 산학협력단 | 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물 |
CN115969847A (zh) * | 2023-02-03 | 2023-04-18 | 华中科技大学 | 罗氟司特在制备治疗心力衰竭的药物中的应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB371800A (en) | 1929-10-21 | 1932-04-28 | Willem Zaadnoordijk | A process of filtering gases and fogs |
GB343664A (en) | 1929-12-27 | 1931-02-26 | William Duncan Grant | Subaquatic rock drilling devices |
GB357903A (en) | 1931-01-05 | 1931-10-01 | Oskar Rosenfelder | Improvements in catamenial appliances and infants' diapers |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
CA2165192C (en) | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
US5728705A (en) | 1993-10-04 | 1998-03-17 | The Trustees Of Columbia University In The City Of New York | Method of inducing vasorelaxation to treat pulmonary hypertension |
GB9401090D0 (en) | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
ATE386531T1 (de) | 1997-02-28 | 2008-03-15 | Nycomed Gmbh | Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse- agonisten |
TR199902646T2 (xx) | 1997-04-25 | 2000-05-22 | Pfizer Inc. | Seks�el bozuklu�un tedavisi i�in pirazolopirimidinonlar. |
FR2762841B1 (fr) * | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | Diazepino-indolones inhibitrices de phosphodiesterases iv |
GB2346877B (en) | 1997-11-12 | 2001-12-05 | Bayer Ag | 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors |
JP3721077B2 (ja) | 1998-04-20 | 2005-11-30 | ファイザー・インク | 性的不全を治療するためのピラゾロピリミジノンcGMPPDE5阻害剤 |
DE19819023A1 (de) | 1998-04-29 | 1999-11-04 | Merck Patent Gmbh | Thienopyrimidine |
TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
JP2002540102A (ja) | 1999-03-22 | 2002-11-26 | ブリストル−マイヤーズ スクイブ カンパニー | cGMPホスホジエステラーゼの縮合ピリドピリダジン阻害剤 |
EP1219609B1 (en) | 1999-09-16 | 2007-04-04 | Tanabe Seiyaku Co., Ltd. | Aromatic nitrogenous six-membered ring compounds |
TW200400821A (en) | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
HUP0401305A2 (hu) * | 2001-01-31 | 2004-10-28 | Pfizer Products Inc. | Tiazolil-, oxazolil-, pirrolil- és imidazolil-savamid-származékok, mint PDE4 izozimek inhibitorai és az ezeket tartalmazó gyógyszerkészítmények |
PL364910A1 (en) | 2001-01-31 | 2004-12-27 | Pfizer Products Inc. | Ether derivatives useful as inhibitors of pde4 isozymes |
US20020165962A1 (en) * | 2001-02-28 | 2002-11-07 | Alvarez Mario F. | Embedded controller architecture for a modular optical network, and methods and apparatus therefor |
DE10135815A1 (de) | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
JP5116940B2 (ja) * | 2001-11-05 | 2013-01-09 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヒドラゾノ−マロニトリル類 |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
BR0310061A (pt) * | 2002-05-16 | 2005-03-01 | Pharmacia Corp | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições |
WO2004072079A1 (en) | 2003-02-11 | 2004-08-26 | Pfizer Limited | Hydrated and anhydrous sildenafil hemi-citrate compound |
EP1634606A1 (en) * | 2003-03-31 | 2006-03-15 | Kyowa Hakko Kogyo Co., Ltd. | Drug for airway administration |
NZ544040A (en) | 2003-05-22 | 2009-03-31 | Nycomed Gmbh | Composition comprising a PDE4 inhibitor and a PDE5 inhibitor |
WO2004105751A1 (en) * | 2003-05-28 | 2004-12-09 | Glaxo Group Limited | Traitement of cardiovascular pathology |
US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
US7132435B2 (en) * | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
RU2006108864A (ru) * | 2003-08-22 | 2007-09-27 | Берингер Ингельхайм Фармасьютиклз, Инк. (Us) | Способы лечения хронического обструктивного заболевания легких (хозл) и легочной гипертензии |
JP2007533760A (ja) | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | 肺高血圧症を治療し管理するための、pde4モジュレーターの使用方法及びpde4モジュレーターを含む組成物 |
-
2006
- 2006-04-12 PT PT111687646T patent/PT2366393E/pt unknown
- 2006-04-12 SI SI200631678T patent/SI2366393T1/sl unknown
- 2006-04-12 CN CN2012100507411A patent/CN102614176A/zh active Pending
- 2006-04-12 AU AU2006237300A patent/AU2006237300B2/en not_active Ceased
- 2006-04-12 NZ NZ561746A patent/NZ561746A/en not_active IP Right Cessation
- 2006-04-12 CA CA2604295A patent/CA2604295C/en not_active Expired - Fee Related
- 2006-04-12 MX MX2007012711A patent/MX2007012711A/es active IP Right Grant
- 2006-04-12 RS RS20130378A patent/RS52944B/en unknown
- 2006-04-12 ME MEP-2013-129A patent/ME01609B/me unknown
- 2006-04-12 BR BRPI0610498-3A patent/BRPI0610498A2/pt not_active IP Right Cessation
- 2006-04-12 EP EP06725734A patent/EP1874309A1/en not_active Withdrawn
- 2006-04-12 PL PL11168764T patent/PL2366393T3/pl unknown
- 2006-04-12 DK DK11168764.6T patent/DK2366393T3/da active
- 2006-04-12 EA EA200702201A patent/EA016037B1/ru not_active IP Right Cessation
- 2006-04-12 JP JP2008507056A patent/JP2008536888A/ja active Pending
- 2006-04-12 KR KR1020077026282A patent/KR101358479B1/ko not_active IP Right Cessation
- 2006-04-12 ES ES11168764T patent/ES2433661T3/es active Active
- 2006-04-12 CN CNA2006800130225A patent/CN101163476A/zh active Pending
- 2006-04-12 WO PCT/EP2006/061557 patent/WO2006111495A1/en active Application Filing
- 2006-04-12 US US11/918,397 patent/US8648100B2/en not_active Expired - Fee Related
- 2006-04-12 EP EP11168764.6A patent/EP2366393B1/en active Active
-
2007
- 2007-09-17 ZA ZA200707930A patent/ZA200707930B/en unknown
- 2007-10-10 IL IL186538A patent/IL186538A0/en not_active IP Right Cessation
- 2007-11-07 NO NO20075662A patent/NO20075662L/no not_active Application Discontinuation
-
2012
- 2012-03-20 IL IL218745A patent/IL218745A0/en unknown
-
2013
- 2013-07-16 JP JP2013147501A patent/JP2013237683A/ja active Pending
- 2013-10-09 CY CY20131100878T patent/CY1114468T1/el unknown
- 2013-10-16 HR HRP20130982TT patent/HRP20130982T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20130982T1 (hr) | Roflumilast za lijeäśenje pulmonalne hipertenzije | |
CY1107498T1 (el) | Φαρμακευτικη συνθεση πepιλαμβανουσα ρεσβepατρολη για την αγωγη φλεγμονωδων αναπνευστικων διαταραχων | |
HRP20170624T1 (hr) | Derivat piridina i pirazina za liječenje kronične opstrukcijske plućne bolesti | |
JP2008518090A5 (hr) | ||
CY1111133T1 (el) | Υπερλεπτο σκευασμα φορμοτερολης | |
UA101653C2 (uk) | Композиція для інгаляції, що містить аклідиній для лікування астми та хронічного обструктивного захворювання легень | |
JP2013231087A5 (hr) | ||
CA2550841A1 (en) | Novel combination of anticholinergic and .beta. mimetics for the treatment of respiratory diseases | |
HRP20221325T1 (hr) | Pripravci i postupci transmukozne apsorpcije | |
JP2008510714A5 (hr) | ||
RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
WO2009112274A3 (en) | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease | |
JP2013542940A5 (hr) | ||
BRPI0409962A (pt) | co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente | |
UA83813C2 (ru) | Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола | |
WO2007112274A3 (en) | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin | |
BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
JP2011511793A5 (hr) | ||
AR039408A1 (es) | Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento | |
JP2008502699A5 (hr) | ||
JP2020516689A5 (hr) | ||
JP2009501230A5 (hr) | ||
WO2008075320A3 (en) | Antilipidemic pharmaceutical compositions and process for preparation thereof | |
CA2519679A1 (en) | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases | |
JP2008536888A5 (hr) |